SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company, today announced that it has received a notice from the European Patent Office (EPO) that no third party oppositions were filed against EPO Patent Grant No. 1246622, relating to pharmaceutical compositions in the form of a non-enteric coated tablet and comprising proton pump inhibitors (PPIs) and one or more buffers. A notice of the publication of the grant of the EPO patent application was issued by the EPO on September 27, 2006 and the period of opposition required under European patent law expired on June 27, 2007. The European patent expires in January 2021 and is licensed to Santarus under its license agreement with the University of Missouri.
